Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 18/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777363 | 0.85 | REN (0.64) | RENPDE4B | |
| SCHEMBL6042551 | 0.83 | REN (0.58) | RENPDE4B | |
| SCHEMBL4603467 | 0.82 | PDE4B (0.49) | RENPDE4B | |
| SCHEMBL3069362 | 0.82 | PDE4B (0.49) | RENPDE4B | |
| SCHEMBL5778929 | 0.82 | PDE4B (0.48) | RENPDE4B | |
| SCHEMBL6234063 | 0.81 | REN (0.49) | RENPDE4B | |
| SCHEMBL4602956 | 0.81 | REN (0.54) | RENPDE4B | |
| SCHEMBL6041283 | 0.81 | REN (0.54) | RENPDE4B | |
| SCHEMBL5814022 | 0.80 | REN (0.57) | RENPDE4B | |
| SCHEMBL4601723 | 0.80 | REN (0.66) | RENPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | REN 1/4885PDE4B 214/4885JAK2 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.